Assessing the Effects of a Buckwheat Beverage on Postprandial Glucose Metabolism on Healthy and T2D Individuals (BUCKFOOD)

April 17, 2019 updated by: University of Aberdeen

Buckwheat is a unique crop because is naturally rich in compounds that have shown beneficial effects on glucose metabolism.

A constant high glucose level in blood after meal consumption is an independent risk factor for cardiovascular complications and death. In order to prevent Type 2 Diabetes Mellitus (T2D) and/or its complications it is important to have a strict control of the blood glucose levels after a meal. There are known therapies for the control of the high glucose blood levels such as agents that act on intestinal digestion of carbohydrates and therapeutic agents that mimic the insulin response after a meal. The combination of these type of agents was commonly prescribed in the treatment of T2D.

The aim of the study is to assess the effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The ability of the buckwheat beverage to modulate postprandial sugar metabolism will be tested in a dietary study in healthy volunteers and people with T2D. Three groups will be recruited; healthy volunteers, individuals with T2D controlled by medication and individuals with T2D controlled by diet and lifestyle only.

For the human volunteers who have T2D controlled by medication, there will be targeted those who have been prescribed metformin only.

The volunteers will visit the Human Nutrition Unit (HNU) three times (a screening visit and two study visits) during the course of the study.

A minimum of two weeks between the study visits will be allowed.

Screening visit:

Once the consent form has been signed, the volunteers taking part in the study will answer a specific health questionnaire and have their blood sugar level measured. The HbA1c (glycated haemoglobin) will be measured using the AS-100 (finger spot blood). We will follow the NHS guideline to establish the values for HbA1c. A normal HbA1c target is below 48 mmol/mol (or 6.5%).

In addition, for the volunteers with T2D, a consultant from the study research team will access the medical records to ensure their eligibility for the study. Permission will be obtained from the volunteers for this via the study consent form.

Dietary study test meal and control meal:

The test meal The buckwheat beverage is prepared from sprouted buckwheat flour without adding any extra sugar, spices or aromas. The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.

The control meal The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.

Both meals will be advised to be consumed within 5 minutes. The T2D volunteers which are on metformin will be advised to take their medication as usual. We will record the dose and time when the metformin will be taken by the volunteers.

Dietary study visits:

Following recruitment, screening and consent, the three groups of volunteers will start the study by random allocation to one of the test meals. On the study day, the volunteers will be advised to come to the HNU in the morning after an overnight fasting (10 h). A cannula will be inserted into the volunteers' arm and baseline blood will be collected. The cannulation and blood sampling will be performed by trained phlebotomists. Additionally a baseline urine sample will be collected. The urine sample either will be brought in by the volunteers in the morning or produced in HNU before the test meals. The volunteers will be served the control and test meal (depending on allocation) and advised that it is to be consumed within five minutes. Volunteers which are on metformin will be asked to take their medication as usual.

For each study visit, blood will be collected at 0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180 and 300 min. The blood will be collected in 4 mL lithium heparin tubes and 4 mL glucose (fluoride oxalate) tubes at each time point. A volume of 96 mL of blood will be collected at each study visit. Additionally a volume of 5 μL blood will be collected for each time point in order to instantly measure the glucose levels. At least two samples will be collected at t=0 in order to obtain a good baseline value.

The movements of the volunteers will be restricted to minimum for the entire blood collection period. They will be asked to stay resting and comfortable position and relaxed for the entire (300 min) sampling period and to not leave the HNU.

After five hours, once all the blood samples have been collected the cannula will be extracted from the volunteer's arm and lunch will be provided.

Study Type

Interventional

Enrollment (Anticipated)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aberdeen, United Kingdom, AB 25 2ZD
        • Recruiting
        • Rowett Institute, University of Aberdeen
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Healthy and T2D (controlled by diet and lifestyle or metformin) volunteers; Age 18+; males and females.

Exclusion Criteria:

For the healthy group:

  • taking prescribed medication
  • HbA1c above 48mmol/mol (or 6.5%)
  • pregnant or breastfeeding
  • blood donation in the last three months
  • unable to give written informed consent
  • eating disorders such as anorexia, bulimia, binge eating or night eating syndrome.
  • significant health issue
  • taking vitamin or mineral supplements (unless they agree to discontinue supplementation 2 weeks or more before the start of the study)
  • Food allergies/intolerances

For the T2D groups:

  • T2D controlled by medication other than metformin
  • pregnant or breastfeeding
  • blood donation in the last three months
  • unable to give written informed consent
  • eating disorders such as anorexia, bulimia, binge eating or night eating syndrome.
  • any other significant health issue other than T2D
  • taking vitamin or mineral supplements (unless they agree to discontinue supplementation 2 weeks before the start of the study)
  • food allergies/intolerances

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control meal
The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
Active Comparator: The test meal
The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post prandial blood glucose (recording cmax)
Time Frame: five hours
Postprandial blood glucose levels after acute consumption of a buckwheat beverage, recording the maximum blood glucose concentration (c max) over the baseline after the consumption of a buckwheat beverage.
five hours
AUC for postprandial glucose
Time Frame: five hours
Area under the curve described by the postprandial glucose level during five hours time
five hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post prandial blood insulin in blood ( including AUC)
Time Frame: five hours
Post prandial blood insulin levels after acute consumption of a buckwheat beverage. AUC (area under curve) for insulin for five hour interval.
five hours
Buckwheat beverage key bioactives bioavailability and metabolism.
Time Frame: five hours
Plasma concentration of key bioactives (inositols and fagomines)
five hours
Urine ratio of myo and D-chiro inositol
Time Frame: 0, 3 and 5 hours
Urine ratio of myo and D-chiro inositol after the consumption of a buckwheat beverage.
0, 3 and 5 hours
Urine glucose concentration
Time Frame: 0, 3 and 5 hours
Glucose concentration in urine after the consumption of a buckwheat beverage.
0, 3 and 5 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 7, 2019

Primary Completion (Anticipated)

September 7, 2020

Study Completion (Anticipated)

March 31, 2021

Study Registration Dates

First Submitted

April 3, 2019

First Submitted That Met QC Criteria

April 17, 2019

First Posted (Actual)

April 22, 2019

Study Record Updates

Last Update Posted (Actual)

April 22, 2019

Last Update Submitted That Met QC Criteria

April 17, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Dietary Intervention

Subscribe